Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1Suspended 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 23Squamous Cell Carcinoma of Head and Neck 14Head and Neck Neoplasms 12Lung Neoplasms 10Uterine Cervical Neoplasms 9Neoplasms 9Cholangiocarcinoma 5Carcinoma, Squamous Cell 5Carcinoma 5Mesothelioma, Malignant 4Carcinoma, Hepatocellular 4Tongue Neoplasms 3Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Breast Neoplasms 3Biliary Tract Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Neoplasms 2Mesothelioma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2

Interventions

ebselen 1Dexamethasone 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Ototoxicity × Cisplatin × Clear all
NCT02382068 2017-11-09

Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin

Ohio State University Comprehensive Cancer Center

Phase NA Withdrawn

Ototoxicity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡